Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2068

Jazz wins approval for bispecific in biliary tract cancer

$
0
0
Jazz Pharmaceuticals earned an FDA approval on Wednesday for zanidatamab, the HER2-targeted bispecific antibody it picked up from Zymeworks for $50 million upfront. The drug, to be marketed as Ziihera, will be ...

Viewing all articles
Browse latest Browse all 2068

Trending Articles